The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Treatment of Churg‐Strauss syndrome without poor‐prognosis factors: A multicenter, prospective, randomized, open‐label study of seventy‐two patients
Open accessAbstract
Objective: To assess the efficacy of systemic corticosteroids (CS) alone as first‐line treatment in patients with Churg‐Strauss syndrome (CSS) without poor‐prognosis factors, as defined by the Five‐Factors Score (FFS), and to compare the efficacy and safety of oral azathioprine (AZA) versus intravenous pulse cyclophosphamide (CYC) as adjuvant immunosuppressive therapy for treatment failure or relapse. Methods: This multicenter, prospective, randomized, open‐label therapeutic trial included 72 patients with newly diagnosed CSS (FFS of 0) treated with CS alone. At treatment failure or relapse, patients were randomized to receive 6 months of oral AZA or 6 pulses of CYC. Analyses were performed according to an intent‐to‐treat strategy. Results: The mean ± SD followup was 56.2 ± 31.7 months. Among the 72 patients studied, 93% achieved remission with CS therapy alone, and 35% relapsed, mainly during the first year of treatment. Among the 19 patients randomized to additional immunosuppression because of treatment failure or relapse, 5 of 10 receiving AZA and 7 of 9 receiving pulse CYC achieved remission, but the difference was not statistically significant. Survival rates in all patients at 1 and 5 years were 100% and 97%, respectively. At the end of followup, 79% of the patients whose disease was in remission required low‐dose CS therapy, mainly to control respiratory disease. CS‐related adverse events were observed in 31% of the 72 patients. Conclusion: In CSS patients with an FFS of 0, survival was excellent, confirming the predictive value of the FFS in this disease. First‐line therapy with CS achieved remission in most patients, but relapses were common, and one‐third of them required additional immunosuppressive therapy. AZA or pulse CYC was fairly effective in treating CS‐resistant disease or major relapses. Over the long term, most patients continued to take oral CS, which might explain the high rate of CS‐related adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Masi, A. T., Hunder, G. G., Lie, J. T., Michel, B. A., Bloch, D. A., Arend, W. P., Calabrese, L. H., Edworthy, S. M., Fauci, A. S., Leavitt, R. Y., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330806 · Cited by 2,215
Churg-Strauss Syndrome Clinical Study and Long-Term Follow-Up of 96 Patients
Guillevin, L., Cohen, P., Gayraud, M., Lhote, F., Jarrousse, B., & Casassus, P. (1999) · Medicine · doi:10.1097/00005792-199901000-00003 · Cited by 1,074
Self-citationBirmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
Luqmani, R. A., BACON, P. A., Moots, R. J., Janssen, B. A., Pall, A. A., Emery, P., Savage, C. O. S., & Adu, D. (1994) · PubMed · Cited by 1,056
Guillevin, L., Lhote, F., Gayraud, M., Cohen, P., Jarrousse, B., Lortholary, O., Thibult, N., & Casassus, P. (1996) · Medicine · doi:10.1097/00005792-199601000-00003 · Cited by 1,000
Self-citationHagen, E. C., Daha, M. R., Hermans, J., Andrassy, K., Csernok, E., Gaskin, G., Lesavre, P., Lüdemann, J., Rasmussen, N., Sinico, R. A., et al. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00807.x · Cited by 740
Sinico, R. A., Di Toma, L., Maggiore, U., Bottero, P., Radice, A., Tosoni, C., Grasselli, C., Pavone, L., Gregorini, G., Monti, S., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21250 · Cited by 691
Antineutrophil Cytoplasmic Antibodies and the Churg–Strauss Syndrome
Sablé-Fourtassou, R., Cohen, P., Mahr, A., Pagnoux, C., Mouthon, L., Jayne, D., Blockmans, D., Cordier, J.-F., Delaval, P., Puechal, X., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-9-200511010-00006 · Cited by 688
Self-citationA Controlled Trial of Azathioprine in Behçet's Syndrome
Yazici, H., Pazarli, H., Barnes, C. G., Tüzün, Y., Özyazgan, Y., Silman, A., Serdaroğlu, S., Oğuz, V., Yurdakul, S., Lovatt, G. E., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002013220501 · Cited by 647
Gayraud, M., Guillevin, L., Le Toumelin, P., Cohen, P., Lhote, F., Casassus, P., Jarrousse, B., & the French Vasculitis Study Group (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200103)44:3<666::aid-anr116>3.0.co;2-a · Cited by 553
Self-citationCyclophosphamide Therapy of Severe Systemic Necrotizing Vasculitis
Fauci, A. S., Katz, P., Haynes, B. F., & Wolff, S. M. (1979) · New England Journal of Medicine · doi:10.1056/nejm197908023010503 · Cited by 526
Cited by
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Wechsler, M. E., Akuthota, P., Jayne, D., Khoury, P., Klion, A., Langford, C. A., Merkel, P. A., Moosig, F., Specks, U., Cid, M. C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702079 · Cited by 1,094
Guillevin, L., Pagnoux, C., Seror, R., Mahr, A., Mouthon, L., & Toumelin, P. L. (2011) · Medicine · doi:10.1097/md.0b013e318205a4c6 · Cited by 951
Self-citationComarmond, C., Pagnoux, C., Khellaf, M., Cordier, J., Hamidou, M., Viallard, J., Maurier, F., Jouneau, S., Bienvenu, B., Puéchal, X., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37721 · Cited by 937
Self-citationKitching, A. R., Anders, H.-J., Basu, N., Brouwer, E., Gordon, J., Jayne, D. R., Kullman, J., Lyons, P. A., Merkel, P. A., Savage, C. O. S., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0204-y · Cited by 928
Emmi, G., Bettiol, A., Gelain, E., Bajema, I. M., Berti, A., Burns, S., Cid, M. C., Cohen Tervaert, J. W., Cottin, V., Durante, E., et al. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-00958-w · Cited by 334
Self-citation
Metadata
- Authors
- Ribi, C., Cohen, P., Pagnoux, C., Mahr, A., Arène, J., Lauque, D., Puéchal, X., Letellier, P., Delaval, P., Cordier, J., & Guillevin, L.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2008-01-31
- Volume
- 58
- Issue
- 2
- Pages
- 586-594
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2082874877
- Cited by
- 335
- References
- 18
- FWCI
- 15.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Churg‐Strauss syndrome without poor‐prognosis factors: A multicenter, prospective, randomized, open‐label study of seventy‐two patients. https://app.cochat.ai/papers/10.1002/art.23198
- The paper
- Ribi, C., Cohen, P., Pagnoux, C., Mahr, A., Arène, J., Lauque, D., Puéchal, X., Letellier, P., Delaval, P., Cordier, J., & Guillevin, L. (2008). Treatment of Churg‐Strauss syndrome without poor‐prognosis factors: A multicenter, prospective, randomized, open‐label study of seventy‐two patients. Arthritis & Rheumatism. https://doi.org/10.1002/art.23198
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.